أوقيانوسيا · الأسواق الإقليمية · Stockhead

TrivarX takes key step towards trial of next-gen cancer imaging technology

نشره Stockhead · أستراليا منذ 1 س

Syntro Health will undertake laboratory formulation activities for the Stabl-Im investigational product, with TrivarX (ASX:TRI) targeting first patient enrolment in ... Read More…

اقرأ المقال كاملًا على Stockhead سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (stockhead.com.au)

يستحق القراءة أيضًا

The Motley Fool Australia

TrivarX takes key step towards trial of next-gen cancer imaging technology

مشاركة

يستحق القراءة أيضًا

3 buy-rated ASX growth shares with big international ambitions

The West confronts the reality of unconditional tolerance

Gingerah's 1GW data centre, 6.7GW renewables project joins EPBC queue

Pumped hydro project scrapped after developer deems it unviable

Australian businesses pull websites offline over PHP threat

Victoria’s government-backed Alice Anderson Fund for women founders scores another $10 million